In:
European Journal of Haematology, Wiley, Vol. 101, No. 1 ( 2018-07), p. 95-105
Kurzfassung:
This multicenter cooperative study aimed to analyze the adverse events ( AE s) associated with tyrosine kinase inhibitors ( TKI s) used as initial treatment for chronic‐phase chronic myeloid leukemia ( CML ‐ CP ) and their impact on outcome. Methods We retrospectively evaluated 450 patients with CML ‐ CP who received TKI s between 2004 and 2014. Results The 5‐year overall survival ( OS ) and event‐free survival ( EFS ) rates were 95.1% and 89.0%, respectively. Patients with comorbidities (46.4%) and aged ≥60 years (50.4%) at diagnosis had significantly inferior OS to those without comorbidities and aged 〈 60. Patients achieved higher rates of major molecular response ( MMR ) at 6 and 12 months after initial treatment with dasatinib or nilotinib compared to imatinib, but final MMR rates were almost the same. Sixty‐six percent of patients required treatment modifications from first‐line TKI therapy; the main reasons were AE s (48.4%) and failure (18%). Grade III ‐ IV AE s in first‐line TKI therapy were significantly correlated to inferior OS / EFS compared to grade 0‐ II AE s. Conclusion Although long‐term outcomes were similar in CML ‐ CP patients treated with each TKI regardless of first‐line TKI selection, severe AE s in first‐line TKI therapy decreased their survival rates. Early change in TKI s is recommended, when faced with severe AE s of specific TKI s.
Materialart:
Online-Ressource
ISSN:
0902-4441
,
1600-0609
DOI:
10.1111/ejh.2018.101.issue-1
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2018
ZDB Id:
2027114-1
Permalink